drugset

Drugs / Autologous Tumor Membrane Vesicles Vaccine

Follow last change May 2025 re-read 3 minutes ago

Autologous Tumor Membrane Vesicles Vaccine

Developed for: cancer of unknown primary site · hypopharynx squamous cell carcinoma · laryngeal squamous cell carcinoma · nasal cavity and paranasal sinus squamous cell carcinoma · nasopharyngeal carcinoma · nasopharyngeal squamous cell carcinoma · oral cavity squamous cell carcinoma · oropharynx squamous cell carcinoma
Investigated by: Emory University · National Cancer Institute (NCI) · National Institutes of Health (NIH)

Trials 1

today NCT06868433 · Ph 1

202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06868433	May 2025 → Jan 2028 expected	cancer of unknown primary site, hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma +4	Emory University	Recruiting	No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Autologous Tumor Membrane Vesicles Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06868433 ↗
Modality	Vaccine	“Vaccines made from a person's tumor cells, such as TMV vaccines” NCT06868433 ↗